<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BAL IN OIL- dimercaprol injection </strong><br>Taylor Pharmaceuticals<br></p></div>
<h1>BAL in Oil Ampules<br>DIMERCAPROL INJECTION, USP</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First">BAL (2, 3-dimercapto-1-propanol) 10%, Benzyl Benzoate 20%, in Peanut Oil<br><br></p>
<p class="Multimediacaption">C<span class="Sub">3</span>H<span class="Sub">8</span>OS<span class="Sub">2</span>   Molecular Weight 124.22</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2ED1FC15-CA74-400E-BFDB-64483B2C590B&amp;name=bal-in-oil-image01.jpg"></div>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Dimercaprol Injection USP is a colorless or almost colorless liquid chelating agent having a disagreeable, mercaptan-like odor.  Each 1 mL sterile BAL in Oil (Dimercaprol Injection USP) contains: 100 mg Dimercaprol in 200 mg Benzyl Benzoate and 700 mg Peanut Oil.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The sulfhydryl groups of dimercaprol form complexes with certain heavy metals thus preventing or reversing the metallic binding of sulfhydryl-containing enzymes. The complex is excreted. The sustained presence of dimercaprol promotes continued excretion of the metallic poisons - arsenic, gold and mercury. It is also used in combination with Edetate Calcium Disodium Injection USP to promote the excretion of lead.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. It is indicated in acute <span class="product-label-link" type="condition" conceptid="436876" conceptname="Toxic effect of lead compound">lead poisoning</span> when used concomitantly with Edetate Calcium Disodium Injection USP.</p>
<p>Dimercaprol Injection USP is effective for use in acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.</p>
<p>Dimercaprol Injection USP is of questionable value in <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">BAL in Oil (Dimercaprol Injection USP) is contraindicated in most instances of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> with the exception of postarsenical <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. The drug should be discontinued or used only with extreme caution if <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal insufficiency</span> develops during therapy.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">There may be local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the site of the injection. A reaction apparently peculiar to children is <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> which may persist during therapy. It occurs in approximately 30% of children. A transient reduction of the percentage of polymorphonuclear leukocytes may also be observed.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Because the dimercaprol-metal complex breaks down easily in an acid medium, production of an alkaline urine affords protection to the kidney during therapy.  Medicinal iron should not be administered to patients under therapy with BAL in Oil (Dimercaprol Injection USP).</p>
<p>BAL in Oil Ampules is formulated with peanut oil. Peanut oil may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in some individuals. Physicians should use caution in prescribing BAL in Oil Ampules for peanut-sensitive patients. Medication and equipment necessary to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> should be available if the product is administered to peanut-allergic patients.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with BAL in Oil. It is also not known whether BAL in Oil can cause fetal harm when administered to a pregnant woman, or can affect reproduction capacity. BAL in Oil should be given to a pregnant woman only if clearly needed.</p>
<p>It is not known whether this drug is excreted in human milk. However, because many drugs are excreted in human milk, caution should be exercised when BAL in Oil is administered to a nursing woman.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">One of the most consistent responses to Dimercaprol Injection USP is a <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span> accompanied by <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. This rise is roughly proportional to the dose administered. Doses larger than those recommended may cause other transitory signs and symptoms in approximate order of frequency as follows: (1) <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and, in some instance, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; (2) <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; (3) a <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> in the lips, mouth and throat; (4) a feeling of constriction, even <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, in the throat, chest, or hands; (5) <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, blepharal spasm, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, and <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>; (6) <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the hands; (7) a <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> in the penis; (8) <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> of the forehead, hands and other areas; (9) <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; and (10) occasional appearance of painful sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>. Many of the above symptoms are accompanied by a feeling of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">unrest</span> and often are relieved by administration of antihistamine.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-10"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Dimercaprol Injection USP is not a controlled substance listed in any other Drug Enforcement Administration schedules. Its use is not known to lead to <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> or abuse.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span></h1>
<p class="First">Dosage exceeding 5 mg/kg will usually be followed by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, beginning within 30 minutes and subsiding within 6 hours following injection.<br><br></p>
<p>A<span class="Italics">MER. HOSP. FORM. SERV., 64:00, Amer. Soc. Hosp. Pharm., 1977.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">By deep intramuscular injection only.  For mild arsenic or gold <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, 2.5 mg/kg of body weight four times daily for two days, two times on the third day, and once daily thereafter for ten days; for severe arsenic or gold <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, 3 mg/kg every four hours for two-days, four times on the third day, then twice daily thereafter for ten days. For mercury <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, 5 mg/kg initially, followed by 2.5 mg/kg one or two times daily for ten days. For acute lead <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, 4 mg/kg body weight is given alone in the first dose and thereafter at four-hour intervals in combination with Edetate Calcium Disodium Injection USP administered at a separate site. For less severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> the dose can be reduced to 3 mg/kg after the first dose. Treatment is maintained for two to seven days depending on clinical response. Successful treatment depends on beginning injections at the earliest possible moment and on the use of adequate amounts at frequent intervals. Other supportive measures should always be used in conjunction with BAL in Oil (Dimercaprol Injection USP) therapy.</p>
<p>BAL in Oil should be inspected visually for particulate matter and discoloration prior to administration.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">3 mL (100 mg/mL) ampules, box of 10 (NDC 11098-526-03).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature.]</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-14"></a><p></p>
<h1>ANIMAL TOXICOLOGY</h1>
<p class="First">The intramuscular LD<span class="Sub">50 </span>in rats is approximately 105 mg/kg; intraperitoneally 140 mg/kg. The intraperitoneal LD<span class="Sub">80</span> in mice is approximately 125 mg/kg.</p>
<p><span class="Italics">JR. PHARM. EXPER.  THER. </span><span class="Bold">87</span>, <span class="Italics">Supplement Aug. 1946.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<h1></h1>
<p class="First">Manufactured by</p>
<p>[Taylor logo]<br>Decatur, IL  62522</p>
<p>BL00N<br>Rev. 10/06</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BAL IN OIL 		
					</strong><br><span class="contentTableReg">dimercaprol injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:11098-526</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dimercaprol</strong> (Dimercaprol) </td>
<td class="formItem"></td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzyl Benzoate</strong></td>
<td class="formItem">200 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Peanut Oil</strong></td>
<td class="formItem">700 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:11098-526-03</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Taylor Pharmaceuticals</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>E1EF33C2-C5FE-B791-7507-BAF1512E50C3</div>
<div>Set id: 2ED1FC15-CA74-400E-BFDB-64483B2C590B</div>
<div>Version: 1</div>
<div>Effective Time: 20070803</div>
</div>
</div> <div class="DistributorName">Taylor Pharmaceuticals</div></p>
</body></html>
